Blood pressure rhythmicity in patients with end stage chronic kidney disease: bromocriptine effect

Authors

  • Oliva Mejía-Rodríguez <p>Instituto Mexicano del Seguro Social,&nbsp;Centro de Investigaci&oacute;n Biom&eacute;dica de Michoac&aacute;n.&nbsp;Morelia, Michoac&aacute;n de Ocampo</p>
  • Humberto Ruiz-Vega <p>Universidad Michoacana de San Nicol&aacute;s de Hidalgo, Divisi&oacute;n de estudios de Posgrado, Facultad de Medicina &ldquo;Dr. Ignacio Ch&aacute;vez&rdquo;.&nbsp;Morelia, Michoac&aacute;n de Ocampo</p>
  • Cleto Álvarez-Aguilar <p>Instituto Mexicano del Seguro Social, Jefatura de Prestaciones M&eacute;dicas Delegaci&oacute;n Michoac&aacute;n, Coordinaci&oacute;n de Planeaci&oacute;n y Enlace Institucional., Morelia, Michoac&aacute;n de Ocampo</p>
  • Marcela Ávila-Díaz <p>Instituto Mexicano del Seguro Social,&nbsp;Centro M&eacute;dico Nacional Siglo XXI,&nbsp; Unidad de Investigaci&oacute;n en Enfermedades Nefrol&oacute;gicas. Ciudad de M&eacute;xico</p>
  • Silvia Palomo-Piñón <p>Instituto Mexicano del Seguro Social,&nbsp;Centro M&eacute;dico Nacional Siglo XXI,&nbsp;Coordinaci&oacute;n de Investigaci&oacute;n en Salud.&nbsp;Ciudad de M&eacute;xico</p>
  • José Ramón Paniagua-Sierra <p>Instituto Mexicano del Seguro Social,&nbsp;Centro M&eacute;dico Nacional Siglo XXI,&nbsp;Hospital de Especialidades,&nbsp;Unidad de Investigaci&oacute;n M&eacute;dica en Enfermedades Nefrol&oacute;gicas.&nbsp;Ciudad de M&eacute;xico</p>

Keywords:

Dopamine, Sympathetic Nervous System, Bromocriptine

Abstract

BACKGROUND: The aim of this paper was to characterize the blood pressure CR in patients with end stage chronic kidney disease (ESCKD) before and after treatment with bromocriptine compared to healthy volunteers.

METHODS: Fifteen patients and nine healthy volunteers were included. Both groups underwent ambulatory 24 hours blood pressure (24 h ABPM). Patients received 2.5 mg every 8 hours of bromocriptine for eight weeks, at the end of the treatment 24 h ABPM was repeated; blood pressure CR was compared before and after treatment and with healthy volunteers. The CR was identified by the method of Cosinor.

RESULTS: 64% of volunteers showed a 24 h CR, against 27% of patients (p < 0.05). After the treatment with bromocriptine 40% of patients showed RC 24 h. The mean arterial pressure decreased from 129 ± 1 mmHg to 106 ± 1 mmHg. A 12 h rhythm was identified in 45% of volunteers and 73% of patients before treatment (p < 0.05) against 60% at the end (p < 0.001), with no statistical difference with volunteers.

CONCLUSIONS: The CR in blood pressure is altered in ESCKD and could be restored with bromocriptine. 12 hours rhythmicity was identified predominantly in patients with ESCKD; this rhythm was also present in the healthy volunteers.

Downloads

Download data is not yet available.

References

Dibner C, Schibler U, Albrecht U. The mammalian circadian timing system: Organization and coordination of central and peripheral clocks. Annu Rev Physiol. 2010;72:517-549.

 

Ko CH, Takahashi JS. Molecular components of the mammalian circadian clock. Human Molecular genetics. 2006;15(2):R271-R277.

 

Witkovsky P, Veisenberger E, LeSauter J, Yan L, Johnson M, Zhang DQ et al. Cellular location and circadian rhythm of expression of the biological clock gene Period 1 in the mouse retina. J Neurosci. 2003;23:7670-7676.

 

Dorenbos R, Contini M, Hirasawa H, Gustincich S, Raviola E. Expression of circadian clock genes in retinal dopaminergic cells. Vis Neurosci. 2007;24:573-580.

 

Pozdeyev N, Tosini G, Li L, Ali F, Rozov S, Lee RH, Iuvone PM. Dopamine modulates diurnal and circadian rhythms of protein phosphorylation in photoreceptor cells of mouse retina. Eur J Neurosci. 2008;27:2691-2700.

 

Julius S. The evidence for a pathophysiologic significance of the sympathetic over activity in hypertension. Clin and Exper Hypertension. 1996;18:305-321.

 

Hermida RC. Ambulatory blood pressure monitoring in the prediction of cardiovascular events and effects of chronotherapy: Rationale and design of the MAPEC study. Chronobiol Int. 2007;24:749-775.

 

Staessen JA, Atkins N, Fagard R. Correlates of the diurnal blood pressure profile in a population study. High Blood Press. 1993;2:271-282.

 

Wühl E, Hadtstein CH, Mehls O, Schaefer F and the ESCAPE Trial Group. Ultradian but not circadian blood pressure rhythms correlate with renal dysfunction in children with chronic renal failure. J Am Soc Nephrol. 2005;16:746-754.

 

Schlaich MP, Socratous F, Hennebry S, Eikelis N, Lambert EA, Straznicky N et al. Sympathetic activation in chronic renal failure. Journal of the American Society of Nephrology. 2009;20(5):933-93.

 

Ziegler MG, Kennedy B, Morrissey E, O’Connor DT. Norepinephrine clearance, chromogranin A and dopamine beta-hydroxylase in renal failure. Kidney International. 1990;37(5):1357-1362.

 

Franchi F, Lazzeri C, Barletta G, Ianni L, Manneli M. Centrally mediated effects of bromocriptine on cardiac sympatovagal balance. Hypertension. 2001;38(1)123-129.

 

Hussain T, Abdul-Wahab E, Khotak DK, Lokhandowla MF. Bromocriptine regulates angiotensin II response on sodium pump in proximal tubules. Hypertension.1998;32:1054-1059.

 

De Fronzo RA. Bromocriptine: a simpatholitic D2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care. 2011;34:789-794.

 

Steardo L, Di Stasio E, Bonuso S, Maj M. The effect of bromocriptine on plasma catecholamine concentrations in normal volunteers. Eur J Clin Pharmacol. 1986;29:713-715.

 

Schobel HP, Schmider RE, Hartman S, Schachinger H, Luft FC: Effects of bromocriptine on cardiovascular regulation in healthy humans. Hypertension. 1995;5(25):1075-1082.

 

Chamontin B, Montastruc JL, Rascol A. How do we explain the antihypertensive effect of bromocriptine? Clinical and experimental contribution. Arch Mal Coeur Vaiss. 1984;77(11):1181-1185.

 

Mejía-Rodríguez O, Alvarez-Aguilar C, Vega-Gómez H, Belio-Caro F, Paniagua-Sierra R. Bromocriptine induces regression of left ventricular hypertrophy in peritoneal dialysis patients. Proc West Pharmacol Soc. 2005;48:122-125.

 

Nelson W, Tong YL, Lee JK. Methods for cosinor rhythmometry. Chronobiologia. 1979;6:305-23.

 

Verdecchia P. Prognostic value of ambulatory blood pressure current evidence and clinical implications. Hypertension. 2000;35:844-851.

 

Amar J, Vernier I, Rossignol E, Bongard V, Arnaud C, Conte JJ et al. Nocturnal blood pressure and 24 hour pulse pressure are potent indicators of mortality in hemodiálisis patients. Kidney Int. 2000;57(6):2485-2491.

 

Hadtstein C, Wühl E, Soergel M, Witte K, Schaefer F. Normative values for circadian and ultradian cardiovascular rhythms in childhood. Hypertension. 2004;43:547–554.

 

Benton LA, Berry SJ, Yates FE. Ultradian rhythmic models of blood pressure variation in normal human daily life. Chronobiologia. 1990;17(2):95-116.

 

Kawamura H, Ozawa Y, Jumbabay M, Mitsubayashi H, Izumi Y, Mahmut M et al. Time-series analysis of systolic blood pressure variation in thirty-three Uygur centenarians in China. Hypertens Res. 2003;26:597-601.

 

Kolloch R, Kobayashi K, DeQuattro V. Dopaminergic control of sympathetic tone and blood pressure: evidence in primary hypertension. Hypertension. 1980;2:390.

 

Sowers JR, Nyby M, Jasberg K. Dopaminergic control of prolactin and blood pressure: altered control in essential hypertension. Hypertension. 1982;4(3):431-7.

 

Penne EL, Neumann J, Klein IH et al. Sympathetic hyperactivity and clinical outcome in chronic kidney disease patients during standard treatment. J Nephrol. 2009;22:208-215.

 

Ritz E, Rump LC. Control of sympathetic activity new insights; new therapeutic targets? Nephrol Dial Transplant. 2010;25:1048-1050.

 

Defronzo RA. Bromocriptine: a sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care. 2011;34(6):789-794.

 

Zeng C, Jose PA. Dopamine receptors: important antihypertensive counterbalance against hypertensive factors. Hypertension. 2011;57:11-7.

Downloads

Published

2018-07-16

Issue

Vol. 55 No. Suplemento 2 (2017)

Section

Original Articles

License

Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.